Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Severe Chronic Plaque Psoriasis”

168 trials

Showing 20 of 168 results

Large-scale testing (Phase 3)Study completedNCT00237887
What this trial is testing

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
Abbott 1,212
Large-scale testing (Phase 3)Study completedNCT03210259
What this trial is testing

The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis

Who this might be right for
Psoriasis
Boehringer Ingelheim 259
Testing effectiveness (Phase 2)Study completedNCT01855880
What this trial is testing

Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients

Who this might be right for
Moderate to Severe Chronic Plaque Psoriasis
AbGenomics B.V Taiwan Branch 54
Testing effectiveness (Phase 2)Study completedNCT00504270
What this trial is testing

R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.

Who this might be right for
Psoriasis
Hoffmann-La Roche 66
Not applicableEnded earlyNCT00402818
What this trial is testing

RESTORE: Raptiva® (Efalizumab) Evaluation of Safety and Treatment Optimization

Who this might be right for
Plaque Psoriasis
Merck KGaA, Darmstadt, Germany 294
Large-scale testing (Phase 3)Not Yet RecruitingNCT07362017
What this trial is testing

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

Who this might be right for
Moderate-to-severe Chronic Plaque Psoriasis
Vanda Pharmaceuticals 300
Testing effectiveness (Phase 2)Study completedNCT01490632
What this trial is testing

A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis

Who this might be right for
PsoriasisSkin DiseasesSkin Diseases, Papulosquamous
Eli Lilly and Company 271
Large-scale testing (Phase 3)Study completedNCT01729754
What this trial is testing

Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)

Who this might be right for
Plaque Psoriasis
Sun Pharmaceutical Industries Limited 1,090
Testing effectiveness (Phase 2)Study completedNCT03000075
What this trial is testing

BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
AbbVie 182
Testing effectiveness (Phase 2)Study completedNCT02949388
What this trial is testing

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Chronic Stable Plaque Psoriasis
Innovation Pharmaceuticals, Inc. 199
Large-scale testing (Phase 3)Study completedNCT02698475
What this trial is testing

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

Who this might be right for
Psoriasis
Janssen Research & Development, LLC 44
Large-scale testing (Phase 3)WithdrawnNCT01936688
What this trial is testing

Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

Who this might be right for
Plaque-type Psoriasis
Sun Pharmaceutical Industries Limited
Not applicableStudy completedNCT05388916
What this trial is testing

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Who this might be right for
Moderate to Severe Chronic Plaque Psoriasis
Novartis Pharmaceuticals 42
Post-approval studies (Phase 4)Study completedNCT06032858
What this trial is testing

Efficacy and Safety of Apremilast in Psoriasis

Who this might be right for
Psoriasis
Ghurki Trust and Teaching Hospital 30
Testing effectiveness (Phase 2)Study completedNCT01987843
What this trial is testing

Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Who this might be right for
Plaque Psoriasis
Tanabe Pharma Corporation 142
Large-scale testing (Phase 3)Study completedNCT03668613
What this trial is testing

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Who this might be right for
Moderate to Severe Chronic Plaque-type Psoriasis
Novartis Pharmaceuticals 84
Post-approval studies (Phase 4)Ended earlyNCT00697593
What this trial is testing

ChangE From Any Systemic psoriasiS therapY to Raptiva

Who this might be right for
Chronic Plaque Psoriasis
Merck KGaA, Darmstadt, Germany 70
Large-scale testing (Phase 3)Ended earlyNCT01163253
What this trial is testing

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Who this might be right for
Psoriasis
Pfizer 2,867
Large-scale testing (Phase 3)Study completedNCT02394561
What this trial is testing

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)

Who this might be right for
Plaque Type Psorisis
Novartis Pharmaceuticals 434
Testing effectiveness (Phase 2)Study completedNCT01225731
What this trial is testing

Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)

Who this might be right for
Psoriasis
Merck Sharp & Dohme LLC 355
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation